Leerink lifts target for McKesson stock to USD 1,070

Published on 10/14/2026 at 16:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

McKesson reports on November 4, 2026. McKesson stock costs EUR 874.10 on October 14, 2026, up 0.98 percent versus NYSE close.

Analyst target and reporting date

Leerink Partners raised its McKesson target to USD 1,070 on October 7, 2026.
McKesson will release second-quarter fiscal 2027 results on November 4, 2026.
McKesson stock costs EUR 874.10 at Lang & Schwarz on October 14, 2026 at 4:46 p.m. CEST, up 0.98 percent versus the NYSE close.
McKesson has a price-to-earnings ratio of 26.02 and market capitalization of USD 113.7 billion.

Schwarzweißfoto eines Lagerarbeiters mit Wagen voller Kartons in großer Lagerhalle — Schwarzweiß-Reportagefoto dokumentiert McKesson Corporation ISIN US58155Q1031 im täglichen Logistikbetrieb mit Arbeiter im Pharma-Vertriebslager, Illustration mit AI erstellt.

Leerink Partners raised its price target for McKesson stock from USD 1,030.00 to USD 1,070.00 on October 7, 2026, according to MarketBeat. The new target is 10.16 percent above the USD 971.34 NYSE price, based on the October 14, 2026 quote. McKesson was at EUR 874.10 at Lang & Schwarz on October 14, 2026 at 4:46 p.m. CEST, while the NYSE price was up 0.98 percent from USD 961.88.

Target reaches USD 1,070

The target increase gives the analyst view a concrete benchmark while McKesson trades below the proposed USD 1,070 level. MarketBeat said Leerink Partners kept an Outperform rating with the target change, making the USD 40.00 increase the central valuation signal in the latest coverage.

MarketBeat also listed 14 Buy ratings and four Holds, with a consensus target of USD 973.19. That consensus is 0.19 percent above the USD 971.34 NYSE price, a much narrower gap than the Leerink target.

Results date is November 4

McKesson will release its second-quarter fiscal 2027 financial results after the market close on November 4, 2026, according to the company's investor-relations release dated September 23, 2026. The conference call is scheduled for 4:30 p.m. ET, giving the next reporting event a precise calendar anchor.

The most recent reported quarter included adjusted earnings of USD 9.93 per share and revenue of USD 105.38 billion, up 7.70 percent year over year, as reported by MarketBeat. The figures provide the operating reference point for the November release.

McKesson price position

The Lang & Schwarz bid was EUR 871.00 and the ask was EUR 877.20 at 4:46 p.m. CEST on October 14, 2026. The NYSE quote stood at USD 971.34, with a session high of USD 977.08 and a session low of USD 965.04.

McKesson's 52-week NYSE range was USD 723.68 to USD 999.00. The current USD 971.34 price sits 2.77 percent below that high, while the market capitalization was USD 113.7 billion on October 14, 2026.

Comparison with peers

McKesson: 0.98 percent, price-to-earnings ratio 26.02, market capitalization USD 113.7 billion.

Cardinal Health (NYSE, USD): 1.43 percent, price-to-earnings ratio 33.68, market capitalization USD 56.9 billion.

Cencora (NYSE, USD): 0.62 percent, price-to-earnings ratio 24.72, market capitalization USD 64.6 billion.

Trading closes at EUR 874.10

McKesson's euro quote at Lang & Schwarz was 0.98 percent above the USD 961.88 NYSE close on October 14, 2026, using the home-exchange daily move as the comparison. The next scheduled corporate date is November 4, 2026, when the company is due to publish second-quarter fiscal 2027 results.

The further course of trading is shown by the continuously updated real-time quote of McKesson stock.